Background and objective: Breast cancer continues to be one of the primary causes of death for women globally. There is a pressing need to find novel therapeutic techniques despite advancements in cancer therapeutics. Here, we examined the anticancer potential of a new viral cause: an attenuated measles strain genetically modified to produce carcinoembryonic antigen (CEA) against breast cancer and derived from the Edmonston vaccination lineage.
Subject and Methods: The VERO-hSLAM cells were use spread the MV. The virus's ability to destroy human Breast cell line (MDA) & REF normal cell line was tested using the crystal violet cytotoxicity assay. Study effected measles vaccine strain against breast cancer cell line (MDA) and REF normal cell line by used different multiplicities of infection (MOIs) from 0.1, 0.5, 1, 3, 5, 10, 15 and 20. for different exposure time (24, 48 and 72 hr.).
Results: At 24, 48, and 72 hours after infection, the data demonstrated a strong cytopathic effect that included widespread syncytia development and enormous cell death.
The outcomes demonstrated that the live attenuated measles virus vaccination may be administered infect and kill breast cancer cells. At 24, 48, and 72 hours after infection, the infected cell line exhibited a significant cytopathic effect, with a noteworthy impact on MDA cells (IC50 values were 4.928 for 24 hours, 2.153 for 48 hours, and 0.2433 for 72 hours).
Conclusion: MeV vaccination has strong oncolytic action against breast cancer cells, as demonstrated by the current study. Virotherapy active and apoptotic instruction results suggest the virus's therapy probable in the treatment of breast cancer.